This biomimetic nanoparticle has the following advantages: (1) accurate targeting of the tumor by modification of HA; (2) activation of T cells by anti-CD3 and anti-CD28 just like DCs; (3) breaking of the immune “brake” of T cells to further promote the activation of T cells by blocking PD-1/PD-L1. The gene discussed is CD274; the disease is neoplasm.